Integra LifeSciences Announces Conference Call for October 2, 2001 to Update Financial Outlook
This conference call will be held in lieu of the Investor Forum originally scheduled to be held at the Congress of Neurological Surgeons meeting in San Diego, California.
The upcoming conference call, which will be hosted by Stuart Essig, President and Chief Executive Officer of Integra, is open to all listeners and will be followed by a question and answer session. Forward-looking guidance will be provided for anticipated growth in product sales, total revenues and operating costs along with a range for earnings per share estimates.
Additionally, clinical and marketing information regarding the Company's recently launched products, including the LICOX® Brain Tissue Oxygen Monitoring System and the NeuraGen™ Nerve Guide, will also be provided on the call.
Access to the live call is available by dialing 973/633-6740. A replay of the broadcast will be available through October 16, 2001 by dialing 973-341-3080 (pin code 2772416).
The Company also announced that financial results for the third quarter of 2001 will be released before the market opens on Wednesday, November 7, followed by a conference call at 9:00 AM EST. Further information about this call will be provided at a later date.
Integra LifeSciences Holdings Corporation develops, manufactures and markets medical devices, implants and biomaterials primarily used in the treatment of cranial and spinal disorders, soft tissue repair and orthopedics. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life.
The Company has its corporate headquarters in Plainsboro, New Jersey and has approximately 585 permanent employees.
Statements made in the upcoming conference call may be forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted results.
Forward-looking statements that may be discussed include, but are not limited to, expected financial results, market potential, and expected sales and potential therapeutic applications of new products.
In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in the Business section of Integra's Annual Report on Form 10-K/A for the year ended December 31, 2000 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
www.integra-Ls.com
CONTACT: Integra LifeSciences Holdings Corporation
John B. Henneman, III, 609/936-2481
jhenneman@integra-ls.com
or
John Bostjancic, 609/936-2239
jbostjancic@integra-Ls.com